

Trial design of MATCH: pros and cons

Keith T. Flaherty, MD Massachusetts General Hospital Cancer Center




Disclosures

Board of Directors: Strata Oncology¥, Scorpion Therapeutics¥ Scientific Advisory Board: Apricity¥, PIC Therapeutics, Tvardi, xCures, Monopteros, Vibliome, ALX Oncology, Fog Pharma, Soley Therapeutics, Alterome, intrECate, Immagene Consultant: Gyges¥, Nextech, Takeda*, Transcode Therapeutics, Novartis*, Roche/Genentech*



NCI-MATCH: investigating therapies beyond tumor types with known benefit



O'Dwyer PJ et al. Nat Med 2023

NCI-MATCH Design



- Metastasis biopsy addresses concern of heterogeneity between primary and metastatic disease
- Uniform diagnostic platform applied across all patient samples
- Imperative to have treatment allocation for as many as possible

Credentialing Drugs for NCI-MATCH

Level of Evidence	Definition
Level 1	FDA-approved for any indication for that target
Level 2	Agent met a clinical endpoint (objective response, PFS, or OS) with evidence of target inhibition
Level 3	Agent demonstrated evidence of clinical activity with evidence of target inhibition at some level

Actionable alteration by cancer type


Level 3B (11%)

Other (63%)

Level 3A (7%)

Level 2B (9%)

Level 1	FDA-recognized biomarker for an FDA-approved drug in the same indication
Level 2A	Standard of care biomarker for an FDA-approved drug in the same indication
Level 2B	Standard of care biomarker for an FDA-approved drug in another indication
Level 3A	Compelling clinical evidence supporting the biomarker as being predictive of drug response in the same indication
Level 3B	Compelling clinical evidence supporting the biomarker as being predictive of drug response in another indication



	Gastrointestinal stromal tumor-				
(7%)	Thyroid cancer-				
evel 2B (9%)	Breast carcinoma -			-	
evel 2D (9%)	Melanoma -			-	
Level 2A (2%)	Glioma -			_	
	Endometrial cancer -				
- Level 1 (7%)	Bladder cancer-				
	Biliary cancer-			-	_
	Non-small-cell lung cancer-				
	Cervical cancer-				
	Esophagogastric carcinoma-	_		-	
ER/PR	Colorectal cancer-	_	_	-	
breast &	Cancer of unknown primary-				
prostate	Salivary carcinoma				
produto	Head and neck carcinoma -				
	Soft-tissue sarcoma-		-	-	
Fusion	Ovarian cancer-				
1 doion	Skin cancer, non melanoma -				
	Uterine sarcoma				
	Appendiceal cancer-				
	Renal cell carcinoma -				
	Germ cell tumor -				
	GNET-			-	
	Pancreatic cancer-				
	Osteosarcoma -		-	-	
	Prostate cancer-				
	Embryonal tumor-				
	Small-cell lung cancer-				
A Charles a	Non-Hodgkin lymphoma				
PHOS HIPPONTACING	Hepatocellular carcinoma				
	Mesothelioma-			1	
	0	25	50	75	100
	Ŭ				
		Perc	Percent of patients		